Martin Olivo

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

M. Piccart, L. Carey, A. Bardia, 2022, npj Breast Cancer.

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.

J. O’Shaughnessy, Wei Zhu, L. Jensen, 2019, Clinical breast cancer.

Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).

A. Bardia, H. Rugo, S. Loibl, 2021 .

Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).

L. Carey, A. Bardia, H. Rugo, 2021 .

Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

Anubha Gupta, O. Majid, L. Reyderman, 2014, Journal of clinical pharmacology.